These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 22185631

  • 1. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
    Takakuwa M, Iwamoto J, Itabashi K.
    Clin Drug Investig; 2012 Feb 01; 32(2):121-9. PubMed ID: 22185631
    [Abstract] [Full Text] [Related]

  • 2. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
    Takakuwa M, Iwamoto J, Konishi M, Zhou Q, Itabashi K.
    J Bone Miner Metab; 2011 Jan 01; 29(1):88-95. PubMed ID: 20533068
    [Abstract] [Full Text] [Related]

  • 3. Five-year experience with risedronate therapy for patients with increased fracture risk: a practice-based observational study.
    Takakuwa M, Iwamoto J.
    Biol Pharm Bull; 2015 Jan 01; 38(1):88-95. PubMed ID: 25744463
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.
    Takakuwa M, Otsuka K, Konishi M, Itabashi K.
    J Int Med Res; 2009 Jan 01; 37(6):1972-81. PubMed ID: 20146897
    [Abstract] [Full Text] [Related]

  • 5. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 01; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
    Frost ML, Siddique M, Blake GM, Moore AE, Marsden PK, Schleyer PJ, Eastell R, Fogelman I.
    Osteoporos Int; 2012 Aug 01; 23(8):2107-16. PubMed ID: 21983795
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY, Kang MI, Park HM, Rhee Y, Moon SH, Yoon HK, Koh JM, Chang JS, Kim IJ, Won YY, Park YS, Choi H, Shin CS, Yoon TR, Yun SC, Chung HY, IDEAL Trial Investigators.
    Arch Osteoporos; 2019 Dec 09; 15(1):3. PubMed ID: 31820121
    [Abstract] [Full Text] [Related]

  • 9. Preoperative bone health assessment and optimization in spine surgery.
    Anderson PA, Kadri A, Hare KJ, Binkley N.
    Neurosurg Focus; 2020 Aug 09; 49(2):E2. PubMed ID: 32738805
    [Abstract] [Full Text] [Related]

  • 10. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec 09; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 11. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug 09; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 12. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    J Bone Miner Metab; 2009 Aug 09; 27(2):168-74. PubMed ID: 19183836
    [Abstract] [Full Text] [Related]

  • 13. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R.
    Lancet Oncol; 2014 Dec 09; 15(13):1460-1468. PubMed ID: 25456365
    [Abstract] [Full Text] [Related]

  • 14. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.
    Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T.
    Bone; 2011 Sep 09; 49(3):328-34. PubMed ID: 21605716
    [Abstract] [Full Text] [Related]

  • 15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul 09; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with risedronate and teriparatide in male osteoporosis.
    Walker MD, Cusano NE, Sliney J, Romano M, Zhang C, McMahon DJ, Bilezikian JP.
    Endocrine; 2013 Aug 09; 44(1):237-46. PubMed ID: 23099796
    [Abstract] [Full Text] [Related]

  • 17. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 09; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 18. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
    Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL.
    Osteoporos Int; 2012 Jan 09; 23(1):285-94. PubMed ID: 21739105
    [Abstract] [Full Text] [Related]

  • 19. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD, Martineau P, Bryanton M, Lix LM.
    Osteoporos Int; 2019 Jul 09; 30(7):1445-1453. PubMed ID: 31016351
    [Abstract] [Full Text] [Related]

  • 20. Effect of stopping risedronate after long-term treatment on bone turnover.
    Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A.
    J Clin Endocrinol Metab; 2011 Nov 09; 96(11):3367-73. PubMed ID: 21865359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.